UBS: Raises Moderna's price target from $50 to $150

Odaily Planet Daily News: UBS has raised its price target for Moderna (MRNA.O) from $50 to $150. Previously reported, the personalized mRNA cancer vaccine developed by Moderna in collaboration with Merck achieved significant success in a Phase III clinical trial targeting high-risk melanoma. This is the world's first mRNA cancer therapy proven effective in a large-scale Phase III trial. Following the announcement, Moderna's stock surged nearly 177% in a single day.